JP2024526356A - R-スポンジンタンパク質の組換えバリアントおよびその使用 - Google Patents

R-スポンジンタンパク質の組換えバリアントおよびその使用 Download PDF

Info

Publication number
JP2024526356A
JP2024526356A JP2024502451A JP2024502451A JP2024526356A JP 2024526356 A JP2024526356 A JP 2024526356A JP 2024502451 A JP2024502451 A JP 2024502451A JP 2024502451 A JP2024502451 A JP 2024502451A JP 2024526356 A JP2024526356 A JP 2024526356A
Authority
JP
Japan
Prior art keywords
seq
rspo1
variant
domain
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024502451A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024526356A5 (https=
Inventor
コロンバ,パトリック
ボティ,パオロ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Universite de Nice Sophia Antipolis UNSA
Original Assignee
Centre National de la Recherche Scientifique CNRS
Universite de Nice Sophia Antipolis UNSA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique CNRS, Universite de Nice Sophia Antipolis UNSA filed Critical Centre National de la Recherche Scientifique CNRS
Publication of JP2024526356A publication Critical patent/JP2024526356A/ja
Publication of JP2024526356A5 publication Critical patent/JP2024526356A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702Regulators; Modulating activity
    • C07K14/4705Regulators; Modulating activity stimulating, promoting or activating activity
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702Regulators; Modulating activity
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/20Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/30Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2024502451A 2021-07-15 2022-07-15 R-スポンジンタンパク質の組換えバリアントおよびその使用 Pending JP2024526356A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP21305993 2021-07-15
EP21305993.4 2021-07-15
EP22305328.1 2022-03-18
EP22305328 2022-03-18
PCT/EP2022/069925 WO2023285686A2 (en) 2021-07-15 2022-07-15 Recombinant variants of r-spondin proteins and their use

Publications (2)

Publication Number Publication Date
JP2024526356A true JP2024526356A (ja) 2024-07-17
JP2024526356A5 JP2024526356A5 (https=) 2025-07-22

Family

ID=82799950

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024502451A Pending JP2024526356A (ja) 2021-07-15 2022-07-15 R-スポンジンタンパク質の組換えバリアントおよびその使用

Country Status (9)

Country Link
US (2) US20240383952A1 (https=)
EP (1) EP4370535A2 (https=)
JP (1) JP2024526356A (https=)
KR (1) KR20240040088A (https=)
AU (1) AU2022311529A1 (https=)
CA (1) CA3225626A1 (https=)
IL (1) IL310154A (https=)
MX (1) MX2024000757A (https=)
WO (1) WO2023285686A2 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230241161A1 (en) * 2020-01-10 2023-08-03 Inserm (Institutnationaldelasanteetdelarecherchemedicale) Rspo1 proteins and their use
CN120813594A (zh) * 2023-01-19 2025-10-17 迪奥根克斯公司 R-spondin蛋白的重组变体及其用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
GB8725529D0 (en) 1987-10-30 1987-12-02 Delta Biotechnology Ltd Polypeptides
US8377653B2 (en) 2005-02-11 2013-02-19 Icosagen Cell Factory Oü Viral expression plasmids for production of proteins, antibodies, enzymes, virus-like particles and for use in cell-based assays
US7790446B2 (en) 2005-02-11 2010-09-07 Kosagen Cell Factory Oü Vectors, cell lines and their use in obtaining extended episomal maintenance replication of hybrid plasmids and expression of gene products
AU2013204484B2 (en) * 2011-07-15 2016-05-12 Oncomed Pharmaceuticals, Inc. RSPO binding agents and uses thereof
WO2013049375A2 (en) * 2011-09-28 2013-04-04 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for modulating beta cell proliferation
US9783784B2 (en) * 2013-01-04 2017-10-10 City Of Hope Methods for establishing and improving the survival of a population of pancreatic progenitor or stem cells
US9777052B2 (en) * 2014-12-02 2017-10-03 The Board Of Regents Of The University Of Oklahoma R-spondin variants, compositions, and methods of use
WO2018140821A1 (en) * 2017-01-26 2018-08-02 Surrozen, Inc. Tissue-specific wnt signal enhancing molecules and uses thereof
JP2021020900A (ja) * 2019-07-29 2021-02-18 国立大学法人北海道大学 糖代謝異常改善剤

Also Published As

Publication number Publication date
KR20240040088A (ko) 2024-03-27
WO2023285686A3 (en) 2023-03-02
EP4370535A2 (en) 2024-05-22
CA3225626A1 (en) 2023-01-19
US20230340044A1 (en) 2023-10-26
IL310154A (en) 2024-03-01
US20240383952A1 (en) 2024-11-21
MX2024000757A (es) 2024-04-18
WO2023285686A2 (en) 2023-01-19
AU2022311529A1 (en) 2024-01-25

Similar Documents

Publication Publication Date Title
KR101993714B1 (ko) 대사 장애를 치료하는데 이용하기 위한 조성물과 방법
RU2671465C2 (ru) Варианты ctla-4
KR20250139414A (ko) 초장기 작용 인슐린-fc 융합 단백질 및 사용 방법
AU2016346870A1 (en) Dual function proteins and pharmaceutical composition comprising same
KR20130010461A (ko) Il―23에 결합하는 피브로넥틴 기반 스캐폴드 도메인 단백질
EP3672621A1 (en) Glp-2 fusion polypeptides and uses for treating and preventing gastrointestinal conditions
CN105837680A (zh) 治疗fgf21相关的病症的方法
CN102516393B (zh) 胰岛素模拟肽融合蛋白和突变体及其应用
US20180280474A1 (en) Treatment of bile acid disorders
US20230340044A1 (en) Recombinant variants of r-spondin proteins and their use
TW202039541A (zh) 多聚體t細胞調節多肽及其使用方法
JP2026021430A (ja) Rspo1タンパク質およびその使用
CN105492459A (zh) 用于治疗糖尿病的修饰的ingap肽
JP2026506476A (ja) R-スポンジンタンパク質の組換えバリアントおよびその使用
CN117980323A (zh) R-spondin蛋白的重组变体及其用途
JP2002335972A (ja) インスリン受容体関連受容体結合蛋白質及びその利用
KR20210082189A (ko) Glp-2 융합 폴리펩티드 및 위장 병태를 치료 및 예방하기 위한 용도

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250711

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250711